<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143116">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02152384</url>
  </required_header>
  <id_info>
    <org_study_id>15406</org_study_id>
    <secondary_id>I2R-MC-BIDU</secondary_id>
    <nct_id>NCT02152384</nct_id>
  </id_info>
  <brief_title>A Study to Compare and Measure the Effects of Insulin Peglispro and Glargine on Meal Time Insulin Requirements</brief_title>
  <official_title>The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on the Dose Response Effect of Prandial Insulin Lispro in Patients With Type 1 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look into how a base dose of insulin peglispro and insulin glargine will
      affect the meal time dose and efficacy of insulin lispro in type 1 diabetics. This study is
      expected to last up to 17 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pharmacodynamics: Plasma Glucose Area Under the Concentration Curve (AUC), Above Pre Meal Baseline for Insulin Lispro</measure>
    <time_frame>Day 30 through Day 34 of study insulin dosing, predose through 5 hours postdose of insulin lispro</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) for Prandial Insulin Lispro</measure>
    <time_frame>Day 29, predose through 5 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Average Glucose Infusion Rate from Euglycemic 2-step Hyperinsulinemic Clamp (M-value)</measure>
    <time_frame>Day 35, last 60 minutes (final step) of euglycemic 2-step hyperinsuinemic clamp</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) for Paracetamol</measure>
    <time_frame>Day 29, predose through 5 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite and Satiety Ratings, as Measured Using Visual Analog Scale (VAS)</measure>
    <time_frame>Days 29 through 34, pre-breakfast through 5 hours post breakfast</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Area Under the Concentration Curve for Triglyceride</measure>
    <time_frame>Day 29, predose through 5 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp</measure>
    <time_frame>Day 35, insulin clearance during lispro infusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Insulin peglispro (with Insulin Lispro)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin preglispro once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine (with Insulin Lispro)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Peglispro</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Insulin peglispro (with Insulin Lispro)</arm_group_label>
    <other_name>LY2605541</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Insulin peglispro (with Insulin Lispro)</arm_group_label>
    <arm_group_label>Insulin Glargine (with Insulin Lispro)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Insulin Glargine (with Insulin Lispro)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a stable (within 0.5 percent (%) from last measure) glycated hemoglobin (HbA1c)
             &lt;9.0%

          -  Have a stable (within 30%) basal insulin dose of 0.2 to 1.0 units per kilogram per
             day (U/kg/day) and a total daily insulin dose (basal + prandial/bolus) &lt;1.5 units per
             kilogram (U/kg)

          -  Have C-peptide &lt;0.3 nanomoles per liter (nmol/L)

          -  Are able and willing to eat the protocol specified standard breakfast and other meals
             as required

        Exclusion Criteria:

          -  Have corrected QT interval (QTc) prolongation &gt;500 milliseconds (ms) or have any
             other abnormality in the 12 lead electrocardiogram (ECG) that, in the opinion of the
             investigator, increases the risks associated with participating in the study

          -  Have an abnormal blood pressure as determined by the investigator

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine (apart from Type 1 Diabetes Mellitus [T1DM]),
             hematological, or neurological disorders

          -  Have fasting triglycerides (TGs) &gt;400 milligrams per deciliter (mg/dL) (4.52
             micromoles per liter [mmol/L])

          -  Have used systemic corticosteroids within 4 weeks prior to randomization

          -  Currently receive insulin pump or insulin degludec

          -  Have poorly controlled diabetes or are known to have poor awareness of hypoglycemia

          -  Have history of gastroparesis or gastrointestinal malabsorption

          -  Require treatment with any drug other than insulin to treat diabetes

          -  Have a previous history of proliferative retinopathy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin LISPRO</mesh_term>
    <mesh_term>Glargine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
